Bli medlem
Bli medlem

Du är här

2020-07-16

DNA Plc Half-Year Financial Report 2020: DNA fared well in the January-June period despite exceptional circumstances – EBITDA and operating result increased

DNA PLC STOCK EXCHANGE RELEASE 16 JULY 2020, 8:30 AM EEST

This is a summary DNA’s Half-Year Financial Report 2020. The complete report is attached to this release and also available at www.dna.fi/investors.

Summary

Unless otherwise stated, the comparison figures in brackets refer to the corresponding period in the previous year (reference period). Figures are unaudited.

Due to delisting of DNA’s share from Nasdaq Helsinki on 3 February 2020, DNA is not subject to reporting obligations as an issuer of shares as set out in the Finnish Securities Markets Act. DNA is still subject to reporting obligations as an issuer of senior unsecured fixed rate notes due 2025 (ISIN: FI4000312095) listed in Nasdaq Helsinki stock exchange.

January–June 2020

  • Total revenue decreased 1% and came to EUR 459 million (463).
  • Mobile revenue grew 5% and amounted to EUR 270 million (258).
  • EBITDA increased 5% and was EUR 162 million (154).
  • Operating result increased 8% and was EUR 76 million (71).
  • Revenue per user (ARPU) for mobile communications increased 5% and was EUR 16.8 (16.0).
  • The number of mobile subscriptions* decreased and was 2,676,000 (2,698,000). The number of postpaid subscriptions grew by 7,000 and the number of prepaid subscriptions decreased by 24,000.
  • The number of fixed subscriptions (telephony, Internet and TV) decreased 1% and was 880,000 (893,000). The number of broadband subscriptions grew by 33,000. 

*) The number of mobile subscriptions includes postpaid, prepaid, Luuri and mobile broadband subscriptions.

Key figures

The calculation method of the key figures presented in this table differs from that of DNA’s previous key figures. The figures in this table are presented the same way as the key figures published by DNA’s parent company Telenor ASA except for the figures for total revenues and EBITDA. The difference in total revenues and EBITDA is due to differences in the classification of certain items. The comparability of the figures and the vocabulary have been described in a press release issued on 28 April 2020, which is available on DNA's website:
https://corporate.dna.fi/press-releases?type=stt1&id=69879917&scrollTo=UJpEOgFgPw1f

EUR million 1–6/2020 1–6/2019 Change, % 1–12/2019
Total revenues 459 463 -1 946
EBITDA 162 154 5 306
- % of total revenues 35 33  32
Comparable EBITDA 162 154 5 310
- % of total revenues 35 33   33
Depreciation and amortisation 86 83  172
Operating result 76 71 8 134
- % of total revenues 17 15  14
Comparable operating result 76 71 8 141
- % of total revenues 17 15   15
Net result before tax 72 66 9
Författare DNA Oyj

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.